IMO Engine Spółka z Ograniczoną Odpowiedzialnością (KRS 0000619496, NIP 1132910716) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. IMO Engine operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 19, 2016.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - IMO Engine
Identity
- Name
- IMO Engine Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 19, 2016
- Registry status as of
- November 21, 2025
- Latest entry
- July 14, 2023
- Founding act
- 17.05.2016 R.
Articles of association history (1)
- May 17, 2016: 17.05.2016 R.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. TERESPOLSKA, 4, 375, 03-813, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Operational status - IMO Engine
Founded
May 19, 2016
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
100.0 K PLN
1,000 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
N/A
Registry entries
16
latest: July 14, 2023
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - IMO Engine.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
